Kenneth B Gordon (Kenneth Gordon, K B Gordon)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Replacement Therapy

Atopic Dermatitis

Top Venues

The British journal of dermatology

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Molly Thapar, Milan Patel, Kenneth B Gordon
Bimekizumab for the treatment of psoriasis. Immunotherapy (2024)
Molly Thapar, Milan Patel, Kenneth B Gordon
Bimekizumab for the treatment of psoriasis. Immunotherapy 16 (7) (2024)
Molly Thapar, Milan Patel, Kenneth B Gordon
Bimekizumab for the treatment of psoriasis. Immunotherapy 16 (7) (2024)
Kristian Reich, Kenneth B Gordon, Bruce E Strober, April W Armstrong, Megan Miller, Y K Shen, Y You, C Han, Y W Yang, Peter Foley, Christopher Ernest Maitland Griffiths
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. The British journal of dermatology (2021)
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Megan Miller, Y K Shen, Yin You, Chenglong Han, Kenneth B Gordon
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. American journal of clinical dermatology 21 (6) (2021)
Kenneth B Gordon, M Lebwohl, Kim A Papp, H Bachelez, J J Wu, R G Langley, Andrew Blauvelt, B Kaplan, M Shah, Y Zhao, R Sinvhal, Kristian Reich
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. The British journal of dermatology (2021)